Table 8.
Effect of ceftriaxone plus sulbactam with VRP1034 on Zinc and Fe levels in blood and tissues after 20 days of treatment.
| Groups | Blood (µg/ml) | Liver (µg/g tissue) | Kidney (µg/g tissue) | Brain (µg/g tissue) | ||||
|---|---|---|---|---|---|---|---|---|
| Zinc | Fe | Zinc | Fe | Zinc | Fe | Zinc | Fe | |
| Control group | 4.11±0.28 | 2.89±0.21 | 38.96±2.45 | 15.65±1.02 | 20.11±1.25 | 9.61±1.58 | 10.25±0.98 | 20.12 |
| Cd exposed group | 6.37±0.55*** | 0.33±0.014*** | 21.04±3.22*** | 8.87±1.56*** | 18.96±1.93ns | 3.67±0.59*** | 6.69±0.71*** | 6.78±1.15*** |
| Ceftriaxone plus sulbactam with VRP1034 group | 5.02±0.19*** | 0.72±0.011*** | 24.56±1.5* | 10.23±2.10ns | 19.44±2.78ns | 5.03±0.97* | 9.85±1.28*** | 13.87±2.31*** |
All data are Mean ± SD of each group. Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group.
***
Where p<0.001 (highly significant)
**
p<0.01(significant)
*
p<0.05 (significant)
Ns
p>0.05 (non significant).